#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Left ventricular hypertrophy in patients with diabetes mellitus: what we don‘t think about?


Authors: Miroslav Gbúr
Authors‘ workplace: I. kardiologická klinika VÚSCH a. s. a LF UPJŠ v Košiciach
Published in: Forum Diab 2021; 10(2): 114-120
Category:

Overview

Left ventricular hypertrophy (LVH) is a common finding in patients with diabetes mellitus (DM). DM and its comorbidities are common in the population and therefore the presence of another disease leading to LVH in a patient with DM can’t be ruled out. Management and prognosis of LVH vary depending on the underlying cause, so its differential diagnosis is very important. The aim of the article is a brief overview of the etiology and diagnostic procedure in patients with left ventricular hypertrophy with a focus on the most clinically important but less frequently diagnosed diseases.

Keywords:

diabetic cardiomyopathy – cardiac amyloidosis – Fabry disease – left ventricular hypertrophy


Sources

1. Levy D, Garrison RJ, Savage DD et al. Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart Study. N Engl J Med 1990; 322(22): 1561–1566. Dostupné z DOI: <http://dx.doi.org/10.1056/nejm199005313222203>.

2. Bluemke DA, Kronmal RA, Lima JA et al. The Relationship of Left Ventricular Mass and Geometry to Incident Cardiovascular Events. The MESA (Multi-Ethnic Study of Atherosclerosis) Study. J Am Coll Cardiol 2008; 52(25): 2148–2155. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2008.09.014>.

3. Levy D, Anderson KM, Savage DD et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108(1): 7–13. Dostupné z DOI: <http://dx.doi.org/10.7326/0003–4819–108–1-7>.

4. Schirmer H, Lunde P, Rasmussen K. Prevalence of left ventricular hypertrophy in a general population; The Tromsø Study. Eur Heart J 1999; 20(6): 429–438. Dostupné z DOI: <http://dx.doi.org/10.1053/euhj.1998.1314>.

5. Beneyto M, Cariou E, Brunel J et al. Tip of the iceberg: a tertiary care centre retrospective study of left ventricular hypertrophy aetiologies. Open Hear 2021; 8(1). Dostupné z DOI: <http://dx.doi.org/10.1136/openhrt-2020–001462>.

6. Baig S, Vijapurapu R, Alharbi F et al. Diagnosis and treatment of the cardiovascular consequences of Fabry disease. QJM 2019; 112(1): 3–9. Dostupné z DOI: <http://dx.doi.org/10.1093/qjmed/hcy120>.

7. Maurer MS, Schwartz JH, Gundapaneni B et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2018; 379(11): 1007–1016. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1805689>.

8. Falk RH, Alexander KM, Liao R et al. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol 2016; 68(12): 1323–1341. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2016.06.053>.

9. Eguchi K, Boden-Albala B, Jin Z et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 2008; 101(12): 1787–1791. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2008.02.082>.

10. Rubler S, Dlugash J, Yuceoglu YZ et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30(6): 595–602. Dostupné z DOI: <http://dx.doi.org/https://doi.org/10.1016/0002–9149(72)90595–4>.

11. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34(1): 29–34. Dostupné z DOI: <http://dx.doi.org/10.1016/0002–9149(74)90089–7>.

12. Tan Y, Zhang Z, Zheng C et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol 2020; 17(9): 585–607. Dostupné z DOI: <http://dx.doi.org/10.1038/s41569–020–0339–2>.

13. Lang RM, Badano LP, Mor-Avi V et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28(1): 1–39. e14. Dostupné z DOI: <http://dx.doi.org/10.1016/j.echo.2014.10.003>.

14. Dostupné z DOI: . 14. Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35(39): 2733–2779. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu284>.

15. Pelliccia A, Sharma S, Gati S et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease: The Task Force on sports cardiology and exercise in patients with cardio vascular disease of the European Society of Cardiology (ESC). Eur Heart J 2021; 42(1): 17–96. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehaa605>.

16. Peguero JG, Lo Presti S, Perez J et al. Electrocardiographic Criteria for the Diagnosis of Left Ventricular Hypertrophy. J Am Coll Cardiol 2017; 69(13): 1694–1703. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2017.01.037>.

17. Burrage MK, Ferreira VM. Cardiovascular Magnetic Resonance for the Differentiation of Left Ventricular Hypertrophy. Curr Heart Fail Rep 2020; 17(5): 192–204. Dostupné z DOI:<http://dx.doi.org/10.1007/s11897–020–00481-z>.

18. Ommen SR, Mital S, Burke MA et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy. Circulation 2020; 142(25): e558-e631. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000000937>.

19. Terryn W, Deschoenmakere G, De Keyser J et al. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. Int J Cardiol 2013; 167(6): 2555–2560. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2012.06.069>.

20. Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017; 38(38): 2879–2887. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx350>.

21. Linhart A, Cecchi F. Common presentation of rare diseases: Left ventricular hypertrophy and diastolic dysfunction. Int J Cardiol 2018; 257: 344–350. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2018.01.006>.

22. Massera D, McClelland RL, Ambale-Venkatesh B et al. Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA. J Am Heart Assoc 2019; 8(8): e012250. Dostupné z DOI: <http://dx.doi.org/10.1161/JAHA.119.012250>.

23. Kittleson MM, Maurer MS, Ambardekar AV et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation 2020; 142(1): e7-e22. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000000792>.

24. Benson MD, Buxbaum JN, Eisenberg DS et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018; 25(4): 215–219. Dostupné z DOI: <http://dx.doi.org/10.1080/13506129.2018.1549825>.

25. Ruberg FL, Grogan M, Hanna M et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 2019; 73(22): 2872–2891. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2019.04.003.

26. Perugini E, Guidalotti PL, Salvi F et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46(6): 1076– 1084. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2005.05.073>.

27. Gillmore JD, Maurer MS, Falk RH et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016; 133(24): 2404– 2412. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021612>.

28. Linhart A, Germain DP, Olivotto I et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail 2020; 22(7): 1076–1096. Dostupné z DOI: <http://dx.doi.org/https://doi.org/10.1002/ejhf.1960>.

29. Echevarria L, Benistan K, Toussaint A et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet 2016; 89(1): 44–54. Dostupné z DOI: <http://dx.doi.org/10.1111/cge.12613>.

30. Mehta A, Beck M, Eyskens F et al. Fabry disease: a review of current management strategies. QJM 2010; 103(9): 641–659. Dostupné z DOI: <http://dx.doi.org/10.1093/qjmed/hcq117>.

31. Yousef Z, Elliott PM, Cecchi F et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J 2013; 34(11): 802–808. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehs166>.

32. Linhart A, Kampmann C, Zamorano JL et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007; 28(10): 1228–1235. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehm153>.

33. Thompson RB, Chow K, Khan A et al. T1 mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging 2013; 6(5): 637–645. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCIMAGING.113.000482>.

34. Vardarli I, Rischpler C, Herrmann K et al. Diagnosis and Screening of Patients with Fabry Disease. Ther Clin Risk Manag 2020; 16: 551–558. Dostupné z DOI: <http://dx.doi.org/10.2147/TCRM.S247814>.

35. Elliott P, Baker R, Pasquale F et al. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart 2011; 97(23): 1957–1960. Dostupné z DOI: <http://dx.doi.org/10.1136/heartjnl-2011–300364>.

36. Paolillo S, Marsico F, Prastaro M et al. Diabetic Cardiomyopathy: Definition, Diagnosis, and Therapeutic Implications. Heart Fail Clin 2019; 15(3): 341–347. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hfc.2019.02.003>.

37. Negishi K. Echocardiographic feature of diabetic cardiomyopathy: where are we now? Cardiovasc Diagn Ther 2018; 8(1): 47–56. Dostupné z DOI: <http://dx.doi.org/10.21037/cdt.2018.01.03>.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Forum Diabetologicum


Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#